Details of Disease

General Information of Disease (ID: DISALD1T)

• Disease Name: Transplant rejection
• Synonyms: engraftment syndrome
• Disease Class: NE84: Transplant rejection
• Definition: A toxicity of hematopoietic stem cell transplantation that manifests as fever, rash and pulmonary deterioration which becomes evident at marrow engraftment. It occurs unexpectedly and is occasionally fatal. It can occur after an autogeneic or an allogeneic hematopoietic cell transplantation.
• Disease Hierarchy:
  DIS6SVEE: Syndromic disease
  DISN1N0F: Stem cell engraftment
  DISALD1T: Transplant rejection
• ICD Code:
  ICD-11: ICD-11: NE84
  ICD-9: ICD-9: 279.5, 996
  Expand ICD-11: 'NE84
  Expand ICD-10: 'T86; 'T86.1; 'T86.3; 'T86.4; 'T86.9
  Expand ICD-9: 279.5,996
• Disease Identifiers:
  MONDO ID: MONDO_0043358
  MESH ID: D006084
  UMLS CUI: C0919746
  MedGen ID: 214709
  SNOMED CT ID: 426768001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Enteric-coated mycophenolate sodium	DMK659W	Approved	NA	[1]
Mizoribine	DMW6F0S	Approved	Small molecular drug	[2]
Odulimomab	DMFAZF6	Approved	Monoclonal antibody	[3]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ATG-Fresenius S	DM4VJ5Q	Phase 3	Antibody	[4]
AEB07	DMJVN89	Phase 2	Small molecular drug	[5]
ASKP-1240	DM1CLKO	Phase 2	Antibody	[6]
AP1903	DM2LU8M	Phase 1/2	NA	[7]
Transplant acceptance inducing cells	DMT8BBY	Phase 1/2	NA	[8]
LM-CD45	DMR7LKC	Phase 1	Antibody	[9]
SAFIRONIL	DM1UIQP	Phase 1	Small molecular drug	[10]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Allotrap-2702	DM9P01M	Discontinued in Phase 2	NA	[11]
AGI-1096	DM0SOBR	Discontinued in Phase 1	NA	[12]
TAFA-93	DMI52NT	Discontinued in Phase 1	Small molecular drug	[13]
Bi-51013	DMO6T1Q	Terminated	NA	[14]
INXC-ICAM1	DMODQW0	Terminated	Antisense drug	[15]
LJP-920	DMAYJ2I	Terminated	NA	[16]
TAK-779	DM0TELR	Terminated	Small molecular drug	[17]
Tolerimab	DMZKIE0	Terminated	Antibody	[18]
XE-9	DMELOW5	Terminated	NA	[19]

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aom-0871	DMYGSYQ	Investigative	NA	[20]
CWF-0808	DM3CYDZ	Investigative	NA	[20]
PG-140	DMZ1NUB	Investigative	NA	[20]
VR-909	DMKHMV3	Investigative	NA	[20]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002879)
• [4] ClinicalTrials.gov (NCT00655343) Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT). U.S. National Institutes of Health.
• [5] What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81.
• [6] ClinicalTrials.gov (NCT01585233) A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Fresenius Biotech GmbH.
• [9] ClinicalTrials.gov (NCT01678443) Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies. U.S. National Institutes of Health.
• [10] Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001 Aug;1(2):227-40.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002986)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016776)
• [13] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018935)
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002854)
• [15] ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011467)
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 783).
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011393)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005614)
• [20] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.